Philip W. Kantoff, MD

home / authors / philip-w-kantoff-md

Articles

Dr. Kantoff on Future Research Efforts in Prostate Cancer

October 23rd 2020

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Dr. Kantoff on the Rationale to Evaluate VERU-111 in mCRPC

Philip W. Kantoff, MD

October 20th 2020

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Dr. Kantoff on the Need to Develop New Therapies in mCRPC

Philip W. Kantoff, MD

October 8th 2020

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Dr. Kantoff on Approaches for Progressive Prostate Cancer Following Androgen Blockade

Philip W. Kantoff, MD

October 1st 2020

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

Dr. Kantoff on Docetaxel Plus Androgen Deprivation Therapy in Prostate Cancer

Philip W. Kantoff, MD

January 26th 2017

Philip W. Kantoff, MD, chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the combination of docetaxel (Taxotere) chemotherapy and androgen deprivation therapy (ADT) in the setting of metastatic hormone-sensitive prostate cancer.

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

Philip W. Kantoff, MD

November 18th 2016

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.